{
    "nctId": "NCT00950911",
    "briefTitle": "Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only",
    "officialTitle": "An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma",
    "overallStatus": "COMPLETED",
    "conditions": "Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Number of Participants Survived",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects currently enrolled in study 20050103, 20050136, or 20050244\n* Subjects must sign the informed consent before any study specific procedures are performed\n\nExclusion Criteria:\n\n* Developed sensitivity to mammalian cell derived drug products during the 20050103, 20050136, or 20050244 study\n* Currently receiving any unapproved investigational product other than denosumab\n* Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment\n* Subject (male or female) is not willing to use 2 highly effective contraception during treatment and for 7 months (women) or 10 months (men) after the end of treatment\n* Male subject with a pregnant partner who is not willing to use a condom during treatment and for additional 10 months after the end of treatment\n* Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}